DK1420827T3 - 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter - Google Patents

5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter

Info

Publication number: DK1420827T3
Authority: DK; Denmark
Prior art keywords: parathyroid hormone; cnac; oral administration; administration agent; hormone fragments
Prior art date: 2001-08-17

Application number

DK02794796T

Other languages

English (en)

Inventor

Simon David Bateman

Moise Azria

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2001-08-17

Filing date

2002-08-16

Publication date

2009-12-21

2002-08-16 Application filed by Novartis Ag filed Critical Novartis Ag

2009-12-21 Application granted granted Critical

2009-12-21 Publication of DK1420827T3 publication Critical patent/DK1420827T3/da

Links

108090000445 Parathyroid hormone Proteins 0.000 title abstract 3
239000000199 parathyroid hormone Substances 0.000 title abstract 2
229960001319 parathyroid hormone Drugs 0.000 title abstract 2
XRTHAPZDZPADIL-UHFFFAOYSA-N 8-[(5-chloro-2-hydroxybenzoyl)amino]octanoic acid Chemical compound OC(=O)CCCCCCCNC(=O)C1=CC(Cl)=CC=C1O XRTHAPZDZPADIL-UHFFFAOYSA-N 0.000 title 1
102000003982 Parathyroid hormone Human genes 0.000 title 1
239000003795 chemical substances by application Substances 0.000 title 1
239000012634 fragment Substances 0.000 title 1
102100036893 Parathyroid hormone Human genes 0.000 abstract 2
208000001132 Osteoporosis Diseases 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000011164 ossification Effects 0.000 abstract 1
239000008194 pharmaceutical composition Substances 0.000 abstract 1
230000004936 stimulating effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
- A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
- A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Epidemiology (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Endocrinology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Oil, Petroleum & Natural Gas (AREA)
Orthopedic Medicine & Surgery (AREA)
Rheumatology (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Immunology (AREA)
Diabetes (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Steroid Compounds (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

DK02794796T 2001-08-17 2002-08-16 5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter DK1420827T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US31304801P	2001-08-17	2001-08-17
PCT/EP2002/009181 WO2003015822A1 (en)	2001-08-17	2002-08-16	5-cnac as oral delivery agent for parathyroid hormone fragments

Publications (1)

Publication Number	Publication Date
DK1420827T3 true DK1420827T3 (da)	2009-12-21

Family

ID=23214149

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK02794796T DK1420827T3 (da)	2001-08-17	2002-08-16	5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter

Country Status (26)

Country	Link
US (4)	US20040242478A1 (da)
EP (1)	EP1420827B8 (da)
JP (2)	JP4959917B2 (da)
KR (1)	KR20040030120A (da)
CN (1)	CN1279981C (da)
AT (1)	ATE443527T1 (da)
AU (1)	AU2002333443C1 (da)
BR (1)	BRPI0211932B1 (da)
CA (1)	CA2453646C (da)
CO (1)	CO5560586A2 (da)
CY (1)	CY1109661T1 (da)
DE (1)	DE60233803D1 (da)
DK (1)	DK1420827T3 (da)
EC (1)	ECSP044961A (da)
ES (1)	ES2333587T3 (da)
HU (1)	HUP0401441A3 (da)
IL (2)	IL159714A0 (da)
MX (1)	MXPA04001418A (da)
NO (1)	NO328069B1 (da)
NZ (1)	NZ531018A (da)
PL (1)	PL210258B1 (da)
PT (1)	PT1420827E (da)
RU (1)	RU2322256C2 (da)
SI (1)	SI1420827T1 (da)
WO (1)	WO2003015822A1 (da)
ZA (1)	ZA200400242B (da)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
PL211976B1 (pl) *	2001-06-01	2012-07-31	Novartis Ag	Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji
EP1420827B8 (en) *	2001-08-17	2009-12-23	Novartis AG	5-cnac as oral delivery agent for parathyroid hormone fragments
AU2003234716A1 (en) *	2002-04-10	2003-10-27	Joel M. Linden	Use of a2a adenosine receptor agonists for the treatment of inflammatory diseases
US20050054557A1 (en) *	2002-05-09	2005-03-10	Goldberg Michael M.	Compositions for delivering parathyroid hormone and calcitonin
MXPA06000807A (es)	2003-07-23	2006-08-23	Novartis Ag	Uso de calcitonina en osteoartritis.
GB0427600D0 (en) *	2004-12-16	2005-01-19	Novartis Ag	Organic compounds
WO2006076692A1 (en) *	2005-01-12	2006-07-20	Emisphere Technologies, Inc.	Compositions for buccal delivery of parathyroid hormone
EP1896134A2 (en) *	2005-06-13	2008-03-12	Rigel Pharmaceuticals, Inc.	Methods and compositions for treating degenerative bone disorders
PE20100241A1 (es)	2005-09-19	2010-04-16	Emisphere Tech Inc	Formas cristalinas de la sal di-sodio del acido n-(5-clorosaliciloil)-8-aminocaprilico
GB0522566D0 (en) *	2005-11-04	2005-12-14	Novartis Ag	Organic compounds
CN101355959B (zh) *	2005-11-10	2013-02-27	密歇根理工大学管理委员会	黑熊甲状旁腺素和使用黑熊甲状旁腺素的方法
AU2007289344B2 (en) *	2006-08-31	2011-04-14	Novartis Ag	Pharmaceutical compositions comprising hGH for oral delivery
KR20150091536A (ko) *	2007-03-02	2015-08-11	노파르티스 아게	칼시토닌의 경구 투여
NZ585080A (en)	2007-11-02	2012-05-25	Emisphere Tech Inc	Composition comprising Vitamin B12 and N-[8-(2-hydroxybenzoyl) amino ]caprylic acid and salts thereof for treating Vitamin B12 deficiency
EP2509996A1 (en)	2009-12-07	2012-10-17	Michigan Technological University	Black bear parathyroid hormone and methods of using black bear parathyroid hormone
WO2012130193A1 (en)	2011-03-31	2012-10-04	Zentiva, K.S.	Non-covalent soluble complexes of teriparatide with polysaccharides and a dosage form of teriparatide for oral administration
CN113713090B (zh)	2015-02-09	2023-06-02	安特拉贝欧有限公司	骨质疏松症的治疗
IL264880B2 (en)	2016-08-17	2024-09-01	Entera Bio Ltd	Preparations for oral administration of active substances
KR101796604B1 (ko) *	2016-08-30	2017-11-10	목포대학교 산학협력단	위장관 흡수증진제를 함유하는 부갑상선 호르몬의 경구 투여 제형

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4692433A (en) *	1983-10-12	1987-09-08	The Regents Of The University Of California	Method and composition for regulating serum calcium levels of mammals
JPH07502507A (ja) *	1991-12-17	1995-03-16	プロクター、エンド、ギャンブル、ファーマスーティカルズ、インコーポレーテッド	ビスホスホネート類及び副甲状腺ホルモンを用いた骨粗鬆症の治療方法
ES2179831T3 (es) *	1992-09-29	2003-02-01	Inhale Therapeutic Syst	Liberacion en los pulmones de fragmentos activos de hormona paratiroidiana.
DK0915911T3 (da) *	1996-08-02	2004-03-08	Ca Nat Research Council	Analoger til parathyreoideahormon til behandling af osteoporose
US5773647A (en) *	1997-02-07	1998-06-30	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
CA2319680C (en) *	1997-02-07	2010-04-20	Emisphere Technologies, Inc.	Compounds and compositions for delivering active agents
US6537965B1 (en) *	1998-11-25	2003-03-25	The General Hospital Corporation	Amino-terminal modified parathyroid hormone (PTH) analogs
EP1175390B1 (en) *	1999-04-05	2005-02-02	Emisphere Technologies, Inc.	Disodium salts, monohydrates, and ethanol solvates
ES2386263T3 (es) *	2000-03-21	2012-08-14	Emisphere Technologies, Inc.	Método de preparación de salicilamidas alquiladas mediante un producto intermedio de dicarboxilato
PL211976B1 (pl) *	2001-06-01	2012-07-31	Novartis Ag	Kompozycja farmaceutyczna do podawania doustnego oraz zastosowanie kompozycji
EP1420827B8 (en) *	2001-08-17	2009-12-23	Novartis AG	5-cnac as oral delivery agent for parathyroid hormone fragments
ES2330638T3 (es) *	2003-07-11	2009-12-14	Novartis Ag	Composiciones farmaceuticas dosificadas en forma oral que contienen un agente de suministro en forma micronizada.

2002
- 2002-08-16 EP EP02794796A patent/EP1420827B8/en not_active Expired - Lifetime
- 2002-08-16 HU HU0401441A patent/HUP0401441A3/hu unknown
- 2002-08-16 US US10/484,331 patent/US20040242478A1/en not_active Abandoned
- 2002-08-16 RU RU2004107899/15A patent/RU2322256C2/ru not_active IP Right Cessation
- 2002-08-16 DE DE60233803T patent/DE60233803D1/de not_active Expired - Lifetime
- 2002-08-16 NZ NZ531018A patent/NZ531018A/xx not_active IP Right Cessation
- 2002-08-16 BR BRPI0211932A patent/BRPI0211932B1/pt not_active IP Right Cessation
- 2002-08-16 CA CA002453646A patent/CA2453646C/en not_active Expired - Lifetime
- 2002-08-16 AU AU2002333443A patent/AU2002333443C1/en not_active Ceased
- 2002-08-16 SI SI200230866T patent/SI1420827T1/sl unknown
- 2002-08-16 IL IL15971402A patent/IL159714A0/xx unknown
- 2002-08-16 ES ES02794796T patent/ES2333587T3/es not_active Expired - Lifetime
- 2002-08-16 AT AT02794796T patent/ATE443527T1/de active
- 2002-08-16 DK DK02794796T patent/DK1420827T3/da active
- 2002-08-16 CN CNB028160843A patent/CN1279981C/zh not_active Expired - Fee Related
- 2002-08-16 PL PL365388A patent/PL210258B1/pl unknown
- 2002-08-16 PT PT02794796T patent/PT1420827E/pt unknown
- 2002-08-16 MX MXPA04001418A patent/MXPA04001418A/es active IP Right Grant
- 2002-08-16 WO PCT/EP2002/009181 patent/WO2003015822A1/en not_active Ceased
- 2002-08-16 JP JP2003520780A patent/JP4959917B2/ja not_active Expired - Fee Related
- 2002-08-16 KR KR10-2004-7002277A patent/KR20040030120A/ko not_active Ceased
2004
- 2004-01-05 IL IL159714A patent/IL159714A/en not_active IP Right Cessation
- 2004-01-13 ZA ZA200400242A patent/ZA200400242B/en unknown
- 2004-01-29 EC EC2004004961A patent/ECSP044961A/es unknown
- 2004-02-10 NO NO20040598A patent/NO328069B1/no not_active IP Right Cessation
- 2004-02-17 CO CO04013136A patent/CO5560586A2/es not_active Application Discontinuation
2006
- 2006-05-30 US US11/443,528 patent/US20060217313A1/en not_active Abandoned
2009
- 2009-06-09 JP JP2009138067A patent/JP2009242410A/ja not_active Withdrawn
- 2009-07-01 US US12/495,966 patent/US20090264367A1/en not_active Abandoned
- 2009-11-25 CY CY20091101231T patent/CY1109661T1/el unknown
2011
- 2011-12-15 US US13/327,114 patent/US9272040B2/en not_active Expired - Fee Related

Also Published As

Publication number	Publication date
KR20040030120A (ko)	2004-04-08
ECSP044961A (es)	2004-03-23
PL365388A1 (en)	2005-01-10
CA2453646C (en)	2008-09-30
MXPA04001418A (es)	2004-05-27
EP1420827A1 (en)	2004-05-26
PT1420827E (pt)	2009-12-15
HUP0401441A2 (hu)	2004-12-28
NO328069B1 (no)	2009-11-23
JP2005501852A (ja)	2005-01-20
US20120088725A1 (en)	2012-04-12
NZ531018A (en)	2006-03-31
AU2002333443B2 (en)	2006-06-29
IL159714A0 (en)	2004-06-20
US20090264367A1 (en)	2009-10-22
WO2003015822A1 (en)	2003-02-27
US9272040B2 (en)	2016-03-01
NO20040598L (no)	2004-02-10
US20060217313A1 (en)	2006-09-28
US20040242478A1 (en)	2004-12-02
BR0211932A (pt)	2004-10-26
PL210258B1 (pl)	2011-12-30
EP1420827B1 (en)	2009-09-23
CA2453646A1 (en)	2003-02-27
RU2004107899A (ru)	2005-05-10
CY1109661T1 (el)	2014-08-13
DE60233803D1 (de)	2009-11-05
SI1420827T1 (sl)	2010-01-29
CN1543357A (zh)	2004-11-03
ES2333587T3 (es)	2010-02-24
ATE443527T1 (de)	2009-10-15
CN1279981C (zh)	2006-10-18
BRPI0211932B1 (pt)	2016-12-06
CO5560586A2 (es)	2005-09-30
JP4959917B2 (ja)	2012-06-27
ZA200400242B (en)	2004-11-18
EP1420827B8 (en)	2009-12-23
RU2322256C2 (ru)	2008-04-20
JP2009242410A (ja)	2009-10-22
AU2002333443C1 (en)	2009-10-08
HUP0401441A3 (en)	2012-09-28
IL159714A (en)	2010-12-30

Publication	Publication Date	Title
DK1420827T3 (da)	2009-12-21	5-CNAC sp, oralt indgivelsesmiddel for parathyroidhormonfragmenter
MXPA03007837A (es)	2004-03-16	Composiciones para suministrar bisfosfonatos.
IL175158A0 (en)	2006-09-05	Tocopherol-modified therapeutic drug compounds
MXPA04008068A (es)	2004-11-26	Metodo para administrar moleculas de glp-1.
MXPA06012980A (es)	2007-06-12	Composiciones y metodos para el suministro mucosal mejorado de la hormona paratiroidea.
AU2003301190A8 (en)	2004-07-14	Administration of capsaicinoids
IL220043A0 (en)	2012-06-28	Methods for producing ??-galactosidase a compositions
ATE500218T1 (de)	2011-03-15	Mittel zur behandlung von erkrankungen, die mit knochenschwund einhergehen, mit ep4-agonist als wirkstoff
GT199700009AA (es)	1999-01-23	Terapia combinada para la osteoporosis
LU91281I2 (fr)	2006-12-19	Preotact-hormone parathyroïde
DE60218842D1 (de)	2007-04-26	Orale verabreichung von parathyroidhormon und calcitonin
WO2004073615A8 (en)	2008-11-20	Deazaflavin compounds and methods of use thereof
TW200511999A (en)	2005-04-01	Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin d derivatives and parathyroid hormone
MXPA04001912A (es)	2004-07-23	Aminobenzofenonas novedosas.
PL370361A1 (en)	2005-05-16	Alkyl urea retinoid agonists i
UA66932C2 (en)	2004-06-15	Complex of eletriptan and sulphobutylether-beta-cyclodextrin, pharmaceutical composition, method for their manufacture and method for treating migraine
AU2003286617A8 (en)	2004-06-03	Calcitonin drug-oligomer conjugates, and uses thereof
PL370459A1 (en)	2005-05-30	Substituted urea retinoid agonists ii
NO20054034L (no)	2005-10-05	Fremgangsmate for behandling av hypotyroidisme.
MXPA03006157A (es)	2003-09-16	Metodo de terapia de reemplazo de hormona y su forma de administracion.
AU2002319223A1 (en)	2002-12-23	Medicament for treating tumours and their metastases using a binding molecule against bone-sialoprotein
TW200509960A (en)	2005-03-16	Compositions and methods for enhanced mucosal delivery and non-infused administration of Y2 receptor-binding peptides and methods for treating and preventing obesity
MXPA05003633A (es)	2005-12-14	2"-oxo-voruscharina y derivados de la misma.
TW200519078A (en)	2005-06-16	2-alkylidene-19-nor-vitamin d derivatives for the treatment of a second hip fracture